Research programme: intranasal anthrax vaccine - NanoBio/Public Health England

Drug Profile

Research programme: intranasal anthrax vaccine - NanoBio/Public Health England

Latest Information Update: 01 Aug 2016

Price : $50

At a glance

  • Originator NanoBio Corporation; Public Health England
  • Class Anthrax vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Anthrax

Most Recent Events

  • 01 Aug 2016 Preclinical trials in Anthrax (Prevention) in USA (Intranasal)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Anthrax in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top